Consequences of Brexit on Biosimilars

Brexit, the United Kingdom's withdrawal from the European Union (EU), has had several consequences on biosimilars. Prior to Brexit, the EU provided a unified regulatory framework for the approval and market access of biosimilars across member states. However, with the UK's departure, the Medicines and Healthcare products Regulatory Agency (MHRA) now oversees the regulation and approval of biosimilars specifically for the UK market. This has led to additional regulatory complexities and increased costs for biosimilar manufacturers who need to navigate separate approval processes for the UK and EU markets. Moreover, the divergence in regulations between the UK and the EU has resulted in uncertainties regarding mutual recognition and potential delays in launching biosimilars in both regions. These consequences have introduced challenges for biosimilar developers and impacted patient access to more affordable treatment options in both the UK and EU markets.

    Related Conference of Consequences of Brexit on Biosimilars

    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    September 24-25, 2025

    5th World Congress on Rare Diseases & Orphan Drugs

    Aix-en-Provence, France
    October 23-24, 2025

    21st Annual Meet on Pharmaceutical Sciences

    Paris, France
    November 11-12, 2025

    6th Annual Congress on Antibiotics and Bacterial Infections

    Amsterdam, Netherlands
    November 13-14, 2025

    21st International Conference on Pharmaceutical Chemistry

    Aix-en-Provence, France
    November 20-21, 2025

    21st Annual Congress on Pharmacology and Toxicology

    Paris, France
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    December 01-02, 2025

    13th International Conference on Clinical Trials

    Vancouver, Canada
    February 23-24, 2026

    3rd World Congress on Biologics and Biosimilars

    London, UK
    March 23-24, 2026

    36th Annual European Pharma Congress

    London, UK
    April 16-17, 2026

    19th European Biosimilars Congress

    Rome, Italy
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands
    May 28-29, 2026

    3rd International Conference on Pharmacognosy

    Madrid, Spain
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy

    Consequences of Brexit on Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in